One possibility is that the gain-of-function end-points that appear to occur for APP are not relevant to the promotion of AD by PSEN1 mutations, a view consistent with the scientific literature that identifies loss-of-function rather than gain-of-function mechanisms (Kelleher and Shen, 2017; Sun et al., 2017). This evidence concerns the gene PSEN1 and Alzheimer disease.